The China State Food and Drug Administration (SFDA) has approved 3SBio's application to conduct the China arm of the multi-center Phase III trial of voclosporin.
Voclosporin is a new generation calcineurin inhibitor licensed from Isotechnika Pharma.
According to the approved protocol, the study will be a Phase III, randomized, multi-center, concentration-controlled comparison study on renal transplant patients.
The company expects to begin patient enrollment in the third quarter of 2012.
3SBio is a biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.
bcs game lsu vs alabama college football college football ncaa football brian van gorder blazing saddles
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.